New concepts of biomarkers and clinical outcomes for therapeutic cancer vaccines in clinical trials

Immunotherapy

Volumn 6, Issue 10, 2014, Pages 1025-1036

  Ogi, Chizuru ^a   Aruga, Atsushi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

biomarker; cancer; immune monitoring; immunotherapy; regulatory science; vaccine

Indexed keywords

CANCER VACCINE; TUMOR MARKER;

BLOOD SAMPLING; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMORAL IMMUNITY; IMMUNOASSAY; MEDLINE; PERIPHERAL LYMPHOCYTE; PHENOTYPE; RETROSPECTIVE STUDY; REVIEW; STANDARDIZATION; T LYMPHOCYTE; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; LYMPHOCYTE; NEOPLASMS; PROCEDURES; STANDARDS; TREATMENT OUTCOME;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LYMPHOCYTES; MONITORING, IMMUNOLOGIC; NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84913615625     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.74     Document Type: Review

References (34)

1. Wolchok JD, Hoos A, O'Day S. Guidance for the evaluation of immune therapy activity in solid tumours: immune-related response criteria. Clin. Cancer Res. 15 (23), 7412-7420 (2009).
2. Keilholz U, Weber J, Finke JH. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J. Immunol. 25 (2), 97-138 (2002).
3. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298-306 (2012).
4. + lymphocytes predict clinical outcome in breast cancer. J. Clin. Oncol. 29, 1949-1955 (2011).
5. Balermpas P, Michel Y, Wangenblast J. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br. J. Cancer 110 (2), 501-509 (2014).
6. Mlecnik B, Tosolini M, Kirilovsky A. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin. Oncol. 29, 610-618 (2011).
7. + lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br. J. Cancer 108, 155-162 (2013).
8. Aarntzen EH, Bol K, Schreibelt G. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma. Cancer Res. 72 (23), 6102-6110 (2012).
9. Small EJ, Fratesi P, Reese DM. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 28, 3894-3903 (2000).
10. Higano CS, Schellhammer PF, Small EJ. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with Sipuleucel-T in advanced prostate cancer. Cancer 115, 3670-3679 (2009).
11. Sheikh NA, Petrylak D, Kantoff PW. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized Phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol. Immunother. 62, 137-147 (2013).
12. Hsueh EC, Morton DL. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Semin. Cancer Biol. 13 (6), 401-407 (2003).
13. Morton DL, Foshag LJ, Hoon DS. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. 216 (4), 463-482 (1992).
14. Koc ON, Redfern C, Wiernik PH. A Phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma. J. Immunother. 33, 178-184 (2010).
15. Giaccone G, Debruyne C, Felip E. Phase III study of adjuvant vaccination with Bec2/Bbcille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organization for Research and Treatment of Cancer 08971-08971B; Silva Study). J. Clin. Oncol. 23, 6854-6864 (2005).
16. Brett BT, Smith SC, Bouvier CV. Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J. Clin. Oncol. 20, 4225-4231 (2002).
17. Gilliam AD, Broome P, Topuzov EG. An international multicenter randomized controlled trial of G17DT in patients with pancreatic cancer. Pancreas 41 (3), 374-379 (2012).
18. + lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol. Immunother. 42, 303-309 (1996).
19. Berd D, Maguire HC, Schuchter LM. Autologous hapten-modified melanoma vaccine as post-surgical adjuvant treatment after resection of nodal metastases. J. Clin. Oncol. 15, 2359-2370 (1997).
20. Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J. Clin. Oncol. 22, 403-415 (2004).
21. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J. Clin. Oncol. 22, 4717-4724 (2004).
22. Lutz E, Yeo CJ, Lillemoe KD. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: a Phase II trial of safety, efficacy, and immune activation. Ann. Surg. 253 (2), 328-335 (2011).
23. Walter S, Weinschenk T, Stenzl A. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 18 (8), 1254-1261 (2012).
24. Gulley JL, Arlen PM, Madan RA. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol. Immunother. 59 (5), 663-674 (2010).
25. Vergati M, Cereda V, Gulley JL. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre-versus post-vaccination. Cancer Immunol. Immunother. 60 (2), 197-206 (2011).
26. Disis ML, Wallace DR, Gooley TA. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J. Clin. Oncol. 27, 4685-4692 (2009).
27. Amin A, Benavides LC, Holmes JP. Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer Immunol. Immunother. 57, 1817-1825 (2008).
28. Gulley JL, Madan RA, Tsang KY. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol. Res. 2, 133-141 (2014).
29. Streitz M, Miloud T, Kapinsky M. Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. Trans. Res. 2 (1), 17 (2013).
30. Tjin EP, Konijnenberg D, Krebbers G. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin. Cancer Res. 17 (17), 5736-5747 (2011).
31. + T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed. Res. Int. 2013, 976383 (2013).
32. Bonchill A, Van Nuffel AM, Corthals J. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin. Cancer Res. 15, 3366-3375 (2009).
33. - T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta1. J. Immunol. 182 (1), 111-120 (2009).
34. Galon J, Pagès F, Marincola FM. The immune score as a new possible approach for the classification of cancer. J. Transl. Med. 10, 1 (2012).